NEW MODELS WITHIN THE HEALTH CARE VALUE CHAIN AND IMPLICATIONS ON THE INTERNATIONAL PHARMACEUTICAL SECTOR (2010)

CHAPTER 1 – THE PHARMACY MARKET........8
1.1 Increasing healthcare costs across the world····8
1.1.1 Health Care costs are a severe business problem........ 8
1.1.2 Opt-Out Incentives........ 9
1.1.3 Manage Supplier Performance...... 9
1.1.4 Disease Management options........ 9
1.2 Pharmaceutical Market Analysis········10
1.2.1 Major therapeutic areas......... 10
1.2.2 Ten companies dominate the worldwide pharmaceutical market.... 10
1.2.3 The US market as the most lucrative market......... 10
1.2.4 Blockbuster drugs are dominating the market......... 11
1.2.5 Pharmaceutical growth.......... 11
1.3 Health Care market··········12
1.3.1 Expenses increase within the pharmaceutical sector............. 12
1.3.2. Sales share across the major regions throughout the world...... 12
1.3.3 Health Care expenditure growth across the countries............ 12
1.4 Major pharmaceutical protagonists·········13
1.4.1 Pharmaceutical Manufacturing – Start of the process chain..... 13
1.4.2 The physician – intermediate within the centre of interests ....14
1.4.3 Pharmaceutical wholesalers..........14
1.4.4 Pharmacists and the portfolio of a pharmacy ..........................14

CHAPTER 2 - CONCENTRATION PROCESS.........15
2.1 The structure of pharmaceutical markets·······15
2.2 Measures affecting prices internationally·······15
2.3 Types of intervention in pharmaceutical markets··········16
2.4 Concentration process within the pharmaceutical field force environment····16
2.5 Concentration process within the wholesale sector·······17

CHAPTER 3 - DISTRIBUTION DEVELOPMENTS.WITHIN PHARMACEUTICALS..........18
3.1 Characteristics of pharmaceutical distribution·········18
3.1.1 The wholesaling reimbursement system is "fundamentally weak”...18
3.1.2 “Specialty" pharmaceutical distribution.......19
3.1.3 Technological changes....19
3.2 Terminology of Health care chain·······19
3.2.1 Existence and objectives of a value chain.........20
3.2.2 Relationship with Consumers .........20
3.3 Logistic problems within the health care distribution chain······21
3.4 Distribution challenges within the health care market in Europe·············22
3.4.1 Background of the distribution challenges......22
3.4.2 Potential reforms of the supply network .......22
3.4.3 Structure of the work analysis .............22
3.4.4 European regulations and trends .............23
3.4.5 Goal and Principles of the European pharmaceutical strategy..........23
3.5 Distribution network and simulations·····24
3.5.1 Distribution within the micro and macro economic environment........24
3.5.2 Distribution logistics....25
3.5.3 Logistics costs ..........25
3.6 Basic conditions and development tendencies around the globe··26
3.7 Conclusion concerning distribution challenges in Europe··········26
CHAPTER 4 - NEW CONCEPTS WITHIN..PHARMACEUTICAL MARKETING......27
4.1 Pharmaceutical marketing mix·······27
4.2 New concepts in pharmaceutical marketing····28
4.3 Social Marketing····28
4.4 Integrated Customer Marketing··29
4.5 Limited product opportunities in pharmaceuticals······30

CHAPTER 5 - NEW DISTRIBUTION MODELS..WITHIN PHARMACEUTICALS.......31
5.1 Cost evaluation as the base for new distribution models·······31
5.2 Increasing control of drug distribution to enhance patient safety ………33
CHAPTER 6 - MARKETING RESEARCHES CHARACTERIZING THE DISTRIBUTION
WITHIN THE PHARMACEUTICAL MARKET.IN GERMANY...33
6.1 Questionnaire conception··········33
6.2 Evaluation and interpretation·········34
6.2.1 System changes and cost reductions implications ...............34
6.2.2 Openness for changes in the distribution cycle in the enterprises......34
6.2.3 How high are the following cost factors being rated? ........34
6.2.4 Physical structure and controlling of the supply chain..........35
6.2.5 Equipment of the national and/or European central storage depots ....35
6.2.6 Trends in the outsourcing process .......36
6.2.7 Supply chain co-operations ............36
6.3 Expectations and openness for new models in the pharmaceutical sec······36
6.4 Key results of empirical study·······37
6.5 Interpretation of the key trends – based on the findings of the empirical study······38
CONCLUSIONS AND PERSONAL CONTRIBUTIONS.......39
ILLUSTRATIONS OVERVIEW...41
LITERATURE OVERVIEW............43